Abstract:The present study investigated the factors associated with recurrence during long-term follow-up in acromegaly and compared the recurrence rate between patients in remission with 2010 vs 2000 consensus criteria. We retrospectively recruited 133 adult acromegalic patients who had undergone transsphenoidal surgery (TSS) from January 2013 to December 2014 and assessed their clinical characteristics, surgical outcomes and recurrence. Surgical remission was defined as normalised insulin-like growth factor 1 (IGF-1) with nadir growth hormone (GH) during an oral glucose tolerance test (OGTT) < 1 mu g/ L no less than 3 months after TSS without adjuvant therapy. Recurrence was defined as persistently reelevated IGF-1 after surgical remission. Cox regression analysis and Kaplan-Meier survival analysis were performed to evaluate the factors associated with recurrence. Remission was achieved in 77 cases (57.9%) after TSS alone. Recurrence was seen in five cases (6.5%) at 12, 12, 12, 36 and 54 months, respectively, after surgery. Cox regression analysis showed that a nadir GH < 0.4 mu g /L (vs 0.4-1.0 mu g /L) at surgical remission (odds ratio [OR] = 0.106; 95% confidence interval [CI] = 0.017-0.645; P = 0.015) and Ki-67 index (OR = 2.636; 95% CI = 1.023-6.791; P = 0.045) were independent factors influencing recurrence. Kaplan-Meier survival analysis showed that the median recurrence-free survival was 36 months (95% CI = 20-52) for patients with nadir GH 0.4-1.0 mu g /L at surgical remission. The median recurrence-free survival for patients with nadir GH < 0.4 mu g /L at surgical remission was much longer (ie, required further follow-up to estimate). A failure of GH suppression under 0.4 mu g /L during an OGTT in patients with normalised IGF-1 and a higher Ki-67 index are independent predictors of recurrence after surgical remission in GH-secreting pituitary adenomas. Compared to patients with nadir GH < 0.4 mu g /L, those with nadir GH 0.4-1.0 mu g /L appear to have a significantly higher risk of recurrence.

Series interpretation to Chinese Expert Consensus on the Diagnosis and Treatment of Acromegaly(2020)(Part 4): Diagnosis and treatment of acromegaly

Series interpretation to Chinese Expert Consensus on the Diagnosis and Treatment of Acromegaly(2020)(Part 1): Genetic causes of acromegaly

[Interpretation of the Chinese Consensus on Endoscopic Diagnosis and Management of Gastrointestinal Submucosal Tumors (version 2018)].

[Interpretation on 2013 Updated Chinese Consensus on the Diagnosis and Treatment of Gastrointestinal Stromal Tumors].

Consensus on chronic gastritis in china ( 9-10 November 2012 Shanghai )

Author Response for "2010 Versus the 2000 Consensus Criteria in Patients with Normalised Insulin‐like Growth Factor 1 after Transsphenoidal Surgery Has High Predictive Values for Long‐term Recurrence‐free Survival in Acromegaly"

Consensus on criteria for acromegaly diagnosis and remission

Analysis of multi-disciplinary team mode in the diagnosis and treatment of acromegaly

[Chinese Expert Consensus on the Surgical Treatment for Adenocarcinoma of Esophagogastric Junction (2018 Edition)].

Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update).

Interpretation of Chinese Expert Consensus on Screening,Prevention and Treatment of Endometrial Carcinoma Associated with Lynch Syndrome(2023)

[Chinese expert consensus on the diagnosis and treatment of chronic graft-versus-host disease (2024)]

Position statement on the diagnosis and management of acromegaly: The French National Diagnosis and Treatment Protocol (NDTP)

[Expert consensus on the early diagnosis and treatment of colorectal cancer in China (2023 edition)]

[Chinese expert consensus on the surgical treatment for adenocarcinoma of esophagogastric junction (Edition 2024)]

Chinese Expert Consensus on Diagnosis and Treatment of Nasopharyngeal Carcinoma: Evidence from Current Practice and Future Perspectives

Approach to the patient with controlled acromegaly and acromegalic arthropathy: clinical diagnosis and management

Interpretation of“guideline and standard for the diagnosis and treatment of breast cancer by Chinese ;Anti-Cancer Association (2015 edition)”:surgical section

National Consensus in China on Diagnosis and Treatment of Patients with Advanced Breast Cancer.

Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE)

Advances in drug treatment of acromegaly